About Biofortuna
Biofortuna is a company based in Birkenhead (United Kingdom) founded in 2008 by Katherine Douglas, Nanette Douglas, and Rachel Douglas. Biofortuna has raised $21.58 million across 9 funding rounds from investors including Enterprise Ventures, Foresight Group and Merseyside Special Investment Fund. The company has 32 employees as of March 31, 2022. Biofortuna has completed 1 acquisition, including Cryoniss. Biofortuna operates in a competitive market with competitors including Novartis, Catalent, Surrozen, Biotage and Curia, among others.
- Headquarter Birkenhead, United Kingdom
- Employees 32 as on 31 Mar, 2022
- Founders Katherine Douglas, Nanette Douglas, Rachel Douglas
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biofortuna Limited
- Date of Incorporation 26 Feb, 2008
- Jurisdiction DEESIDE, WALES
-
Annual Revenue
$1.44 M (USD)-12as on Mar 31, 2018
-
Net Profit
-$1.34 M (USD)-32as on Mar 31, 2018
-
EBITDA
-$1.57 M (USD)-17as on Mar 31, 2018
-
Total Equity Funding
$21.58 M (USD)
in 9 rounds
-
Latest Funding Round
$303.19 K (USD), Grant
Feb 20, 2026
-
Investors
Enterprise Ventures
& 5 more
-
Employee Count
32
as on Mar 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Biofortuna
Biofortuna has successfully raised a total of $21.58M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $303.19 thousand completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Grant — $303,192
-
First Round
First Round
(11 May 2010)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2026 | Amount | Grant - Biofortuna | Valuation |
investors |
|
| Mar, 2021 | Amount | Series A - Biofortuna | Valuation |
investors |
|
| Aug, 2018 | Amount | Series A - Biofortuna | Valuation |
investors |
|
Investors in Biofortuna
Biofortuna has secured backing from 6 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Enterprise Ventures, Foresight Group and Merseyside Special Investment Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A fund focused on supporting SMEs with alternative finance.
|
Founded Year | Domain | Location | |
|
Early and Growth stage Venture Debt firm that does debt investments in the UK
|
Founded Year | Domain | Location | |
|
Investment solutions are provided by Catapult Ventures for growth.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biofortuna
Biofortuna has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cryoniss.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of biobanking services for life sciences industries
|
2018 |
Financial Statements - Biofortuna
Biofortuna Comparisons
Competitors of Biofortuna
Biofortuna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Surrozen, Biotage and Curia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
|
| domain | founded_year | HQ Location |
CDMO offering drug and biologics development services
|
|
| domain | founded_year | HQ Location |
Selective Wnt agonists are developed for human tissue regeneration.
|
|
| domain | founded_year | HQ Location |
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
|
|
| domain | founded_year | HQ Location |
Drug research, development, testing, and consulting services are provided.
|
|
| domain | founded_year | HQ Location |
Protein therapeutics are developed and manufactured by WuXi Biologics.
|
Frequently Asked Questions about Biofortuna
Biofortuna was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Biofortuna is headquartered in Birkenhead, United Kingdom. It is registered at Birkenhead, Merseyside, United Kingdom.
Biofortuna is a funded company, having raised a total of $21.58M across 9 funding rounds to date. The company's 1st funding round was a Series A of $4.5M, raised on May 11, 2010.
As of Mar 31, 2022, the latest employee count at Biofortuna is 32.
Annual revenue of Biofortuna is $1.44M as on Mar 31, 2018.
Biofortuna was established in 2008 in Birkenhead, United Kingdom, within the biotechnology sector. Operations focus on contract manufacturing for immunoassays and molecular diagnostics, complemented by regulatory services. These activities support diagnostic product development and compliance needs for clients in healthcare and life sciences. The company is led by co-founders Katherine Douglas, Nanette Douglas, and Rachel Douglas.
Biofortuna has made 1 acquisition, including Cryoniss.
Biofortuna has 6 investors. Key investors include Enterprise Ventures, Foresight Group, Merseyside Special Investment Fund, Catapult Ventures, and David Whitcombe.
The valuation of Biofortuna is $476.6M as of Aug 2018.